Amylyx co-CEO Joshua B. Cohen sells 61,895 shares

Available on EDGAR 11/12/2026 - 04:00 PM EST Accepted by SEC EDGAR 11/12/2026 - 04:00 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Joshua B. Cohen, Co-Chief Executive Officer of Amylyx Pharmaceuticals, Inc. (AMLX), reported selling 38,105 shares at a weighted-average price of $29.3933 and 61,895 shares at a weighted-average price of $30.1098 on November 9, 2026. The sales were made under a Rule 10b5-1 trading plan adopted on May 11, 2026. Individual sale prices ranged from $28.74 to $29.73 for the first transaction and from $29.74 to $30.29 for the second.

Insider Trade Summary 10b5-1

Net Seller: 100,000 shares

Net Sell 2 txns

Insider Cohen Joshua B

Role Co-Chief Executive Officer

Sold 100,000 shs ($2.98M)

Share of Position Sold 2.8%

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	38,105	$29.3933	$1.12M
Sale	Common Stock F1, F3	61,895	$30.1098	$1.86M

Holdings After Transaction: Common Stock — 3,513,123 shares (Direct)

Holdings Before and After: Common Stock, 3,613,123 to 3,513,123 shares (Direct)

Other Insiders: 2 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (3)

1. F1. The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026.
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.74 to $29.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
3. F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.74 to $30.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Key Figures

Shares sold (first transaction): 38,105 shares Weighted-average sale price (first transaction): $29.3933 per share Shares sold (second transaction): 61,895 shares +1 more

4 metrics

Shares sold (first transaction) 38,105 shares November 9, 2026

Weighted-average sale price (first transaction) $29.3933 per share November 9, 2026

Shares sold (second transaction) 61,895 shares November 9, 2026

Weighted-average sale price (second transaction) $30.1098 per share November 9, 2026

Key Terms

Rule 10b5-1 trading plan, weighted average price

2 terms

Rule 10b5-1 trading plan regulatory

"sales were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many AMLX shares did Joshua B. Cohen sell, and at what prices?

Joshua B. Cohen reported two sales on November 9, 2026: 38,105 shares at a weighted-average $29.3933 and 61,895 shares at a weighted-average $30.1098. Individual sale prices ranged from $28.74 to $29.73 for the first transaction and from $29.74 to $30.29 for the second.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cohen Joshua B

(Last) (First) (Middle)

C/O AMYLYX PHARMACEUTICALS, INC.

55 CAMBRIDGE PARKWAY, SUITE 6W

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Amylyx Pharmaceuticals, Inc. [ AMLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Co-Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/09/2026		S(1)		38,105	D	$29.3933(2)	3,575,018	D
Common Stock	11/09/2026		S(1)		61,895	D	$30.1098(3)	3,513,123	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.74 to $29.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.74 to $30.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

	/s/ Joshua B. Cohen	11/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)